Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2012 - 2026)

Enanta Pharmaceuticals' Preferred Stock Liabilities history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Preferred Stock Liabilities fell 2.89% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 2.89% YoY) and the FY2025 annual result came in at $1.3 million, down 2.89% from the prior year.
• Preferred Stock Liabilities was $1.3 million for Q1 2026 at Enanta Pharmaceuticals, roughly flat from $1.3 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $1.5 million in Q1 2022 and bottomed at $1.3 million in Q3 2025.
• A 5-year average of $1.4 million and a median of $1.4 million in 2022 frame the typical range for Preferred Stock Liabilities.
• Peak annual rise in Preferred Stock Liabilities reached 1.83% in 2022, while the deepest fall reached 5.51% in 2022.
• Enanta Pharmaceuticals' Preferred Stock Liabilities stood at $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then dropped by 5.13% to $1.3 million in 2024, then slipped by 2.89% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Business Quant data shows ENTA's Preferred Stock Liabilities at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.